Bristol-Myers Squibb rebuffed again by Supreme Court on $1.2B Gilead patent dispute
Douglas Rissing/iStock via Getty Images


The US Supreme Court on Monday again declined to rehear Bristol-Myers Squibb's (NYSE:BMY) case that seeks to reinstate a $1.2B patent settlement against Gilead Sciences (NASDAQ:GILD).
The case is between Bristol's Juno Therapeutics and Gilead (GILD) unit Kite Therapeutics. The patent issue involves Kite's CAR-T therapy Yescarta (axicabtagene ciloleucel) for large B-cell lymphoma.

Kite was sued in 2017 by Juno and Sloan Kettering Institute for Cancer Research arguing that it copied technology that was licensed to Juno. A federal court agreed, awarding Juno $1.2B, which was later overturned by a federal appeals court which found the patent invalid.